Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alzamend Neuro Inc
(NQ:
ALZN
)
2.090
UNCHANGED
Streaming Delayed Price
Updated: 3:51 PM EDT, Aug 7, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
458
Open
2.090
Bid (Size)
2.020 (1)
Ask (Size)
2.750 (1)
Prev. Close
2.090
Today's Range
2.090 - 2.090
52wk Range
2.020 - 63.00
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of AL001 involving Patients with Bipolar Disorder and Alzheimer's Disease
August 06, 2024
Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of AL001 involving Patients with Bipolar Disorder and Alzheimer's Disease
Via
News Direct
Exposures
Product Safety
Revolutionary Magnetic Therapy Could Speed Up Bipolar Treatment
August 06, 2024
New research suggests that powerful magnets could effectively treat bipolar disorder. This therapy, which is known as accelerated intermittent theta burst stimulation (iTBS), uses magnetic waves...
Via
PressReach
Exposures
Product Safety
Performance
YTD
-77.28%
-77.28%
1 Month
-54.55%
-54.55%
3 Month
-60.42%
-60.42%
6 Month
-76.34%
-76.34%
1 Year
-96.44%
-96.44%
More News
Read More
Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder and Alzheimer’s Disease
August 06, 2024
Via
PressReach
Exposures
Product Safety
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder
August 06, 2024
Via
PressReach
Exposures
Product Safety
Headline
August 06, 2024
Via
News Direct
Exposures
Product Safety
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Alzheimer’s Disease
August 05, 2024
Via
PressReach
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder
August 06, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
EXCLUSIVE: Alzamend Neuro To Assess AL001 Alzheimer's Candidate Against Commonly Marketed Lithium Salt In Phase 2 Head-To-Head Study
August 05, 2024
Via
Benzinga
Exposures
Product Safety
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Alzheimer’s Disease
August 05, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
June 20, 2024
Via
Benzinga
Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
July 31, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
June 14, 2024
Via
Benzinga
Alzamend Neuro Announces Reverse Stock Split
July 12, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
June 13, 2024
Via
Benzinga
Alzamend Neuro Announces Favorable Decision from Nasdaq Hearings Panel
May 22, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
May 10, 2024
Via
Benzinga
Alzamend Neuro Announces Initial Closing of Private Placement
May 14, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
EXCLUSIVE: Alzamend Neuro To Raise Up To $25M Via Private Placement Of Preferred Shares
May 09, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
May 08, 2024
Via
Benzinga
Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million
May 09, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Halts Equity Offering Program, Prioritizing Shareholder Value Amid Strategic Shift, Shares Slide
May 07, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
May 03, 2024
Via
Benzinga
Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program
May 07, 2024
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro And 2 Other Stocks Under $5 Insiders Are Buying
April 24, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
April 16, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.